Form 4: Gilead Executive Johanna Mercier Sells Shares

Gilead Sciences Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of common stock via a 10b5-1 plan.

Summary

• Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, sold a total of 3,000 shares of common stock on June 15, 2026.
• The sales were executed in three tranches at weighted average prices of $123.4166, $123.9958, and $125.40.
• Following these transactions, Mercier retains beneficial ownership of 124,234 shares of Gilead common stock.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-existing, automated trading plan.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating the transaction was not based on non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock appreciation, though this was a scheduled sale.

Risks

• Market volatility affecting the price of GILD shares.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the investment community.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential insider trading allegations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Johanna Mercier, Stock Sale